Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted treatments for individuals suffering from autoimmune disorders. Its lead candidate is IMVT-1402 (imeroprubart), a fully human monoclonal antibody designed to inhibit the neonatal fragment crystallizable receptor (FcRn) and lower levels of pathogenic immunoglobulin G antibodies. The company develops treatments intended for subcutaneous delivery via an autoinjector across multiple disease areas, including endocrinology, rheumatology, neurology, and dermatology. Its prospective customer and patient base includes individuals affected by conditions such as Graves' disease, difficult-to-treat rheumatoid arthritis, cutaneous lupus erythematosus, and Sjögren's disease.

The company directs its clinical programs toward patient populations across the United States and Europe, having also evaluated IMVT-1402 in clinical trials conducted in New Zealand. The provided excerpt does not disclose the location of Immunovant's corporate headquarters or specific facility counts.

Summary of the business section of Immunovant's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 31, 2026, we had 315 full-time permanent employees, primarily in the U.S.”